Monday, August 2, 2021
wellness India Expo
Home Tags COVAXIN

Tag: COVAXIN

Phase-3 trial results show COVAXIN is 77.8% effective against symptomatic COVID-19

Efficacy analysis demonstrates COVAXIN to be 93.4% effective against severe symptomatic COVID-19. Efficacy data demonstrates 65.2% protection against the SARS-CoV-2, B.1.617.2 Delta variant..................................

COVAXIN pricing based on many factors, says Bharat Biotech as it...

It is emblematic that Bharat Biotech has not sought Indemnity from the Government of India for any adverse events from COVAXIN...................

Bharat Biotech clarifies on the US-FDA’s EUA denial for COVAXIN

As per Bharat Biotech, its US partner, Ocugen has received a recommendation from the FDA to pursue Biologics License Applications (BLA) path for COVAXIN, which is full approval instead of EUA...................

Ocugen expands COVAXIN commercialization rights to include Canada

Ocugen to have exclusive co-development, manufacturing, and commercialization rights to COVAXIN in Canada, in addition to its existing US rights.....................

Indian Immunologicals to help augment Covaxin production

The Managing Director of Indian Immunological Limited, Dr K Anand Kumar said that the IIL is planning to start the production of  drug substance for Covaxin from next month, June 15, and send out the first batch to Bharat Biotech limited by July.......................

From vaccine to vaccination: It takes 120 days for a Covaxin...

The timeline for vaccine supplies to reach the depots of the State and Central Governments from Bharat Biotech’s facilities is around two days............................

DCGI green signal to COVAXIN’s Phase II/III clinical trial in 2-18...

Hyderabad based Bharat Biotech to conduct clinical trials in 525 healthy volunteers........................

PHDCCI urges GOI to take steps for scaling up Covid-19 vaccine...

PHD Chamber has called for immediate steps to facilitate voluntary licensing for scaling up production of Covaxin, Covishield and other vaccines to meet Covid-19 vaccination demand in India..........................

COVAXIN demonstrates interim clinical efficacy of 78% in phase 3 trials

The second interim results showed India’s First COVID-19 Vaccine had demonstrated strong primary efficacy against severe COVID-19 disease.......................

Bharat Biotech to ramp up Covaxin production by 700 million doses...

The capacity expansion has been implemented across multiple facilities in Hyderabad and Bangalore, to reach ~ 700 million doses per year, one of the largest production capacities for Inactivated viral vaccines worldwide.................................